China has seen a significant shift in clinical research regulatory frameworks and processes since 2015. China is now more aligned with international standards especially the USFDA enabling biotech firms to streamline processes and timelines, which has significantly recharged biotech innovation.
The purpose of this report is to understand three points below:
- Recent changes in the regulatory landscape in China
- Strategies biotech companies can put in place to accelerate their development in China
- Key benefits for biotech companies to run clinical trials in China